HIV capsid inhibitor may offer long-term viral suppression
One in six South Africans drug resistant before starting HIV treatment
People stay on PrEP for 14 months on average in the US, study finds
Are CD4 counts still useful in the 'treat all' era?
Multiple benefits to scaling up universal test and treat in Africa
Long-acting injectable treatment maintains viral suppression
‘Molecular scissors’ successfully remove HIV genes from all tissues in infected monkeys
Integrase inhibitor treatment leads to greater weight gain
How many people who have used PrEP get HIV the same year? New York study finds out
Chronic obstructive pulmonary disease (COPD) increases the risk of heart attack in people with HIV
The length of time Americans with HIV remain infectious is falling, but slowly
Neural tube defects and integrase inhibitors: still waiting for stronger evidence
Hepatitis C drops among HIV-positive London gay men after direct-acting antiviral scale-up
HIV infections lowered by 30% in universal testing and treatment study
Descovy is non-inferior to Truvada for daily PrEP
Sudden cardiac death is more common in people with HIV
Integrase inhibitors give greater chance of viral suppression at delivery in pregnant women
Women with HIV may have higher breast cancer mortality
